Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer

<div>(a) Map of the Horizon Discovery PDL1 Reference Standard panel demonstrating negative, low, medium, and strong protein expression (Data provided by Horizon Discovery). (b) Histogram of IHC-determined protein and RNAScope-determined mRNA expression of PDL1 in the Horizon Discovery custom cell line panel. IHC was performed with 3 different antibodies (Abcam (28-8), Spring Bioscience (SP142), and Cell Signalling (405.9A11)) and on the Bondmax and Benchmark automated platforms. IHC was quantified using the QuPath software. RNAScope was quantified using SpotStudio (ACD).</div>

Journal of Oncology

fig1

Figure 1

Figure 1: Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer 

Figure 1 | Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer 